Neuropeptides represent an active area of preclinical and biochemical research. Semax and adamax are two structurally related synthetic peptides of interest to researchers studying neuropeptide pharmacology.
What’s the difference between adamax vs. semax? Here’s a research-based look at these two neuropeptides.
What Is Semax?
Semax is a synthetic peptide derived from a fragment of adrenocorticotropic hormone (ACTH). Specifically, it is a modified ACTH(4–10) fragment extended with a Pro-Gly-Pro sequence. It was developed in Russia in the late 20th century and has been studied primarily in Russian clinical and preclinical literature.
In research settings, Semax has been administered intranasally, a delivery route of interest because it allows peptides to bypass hepatic first-pass metabolism, potentially improving central nervous system availability.
Semax Mechanism of Action
Semax does not act through a single pathway. Instead, research suggests it influences brain function through multiple overlapping biological mechanisms.
Semax has been investigated across several biochemical and neurological research models. Key areas of study include:
Neurotrophic Pathways In vitro and animal studies have examined Semax’s influence on gene expression related to brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) — proteins involved in neuronal survival and synaptic plasticity.
Oxidative Stress and Inflammatory Signaling Models Semax has been studied in ischemic and hypoxic models, where researchers have examined its effects on oxidative stress markers, inflammatory signaling pathways, and neuronal survival metrics.
Receptor Activity Research suggests Semax may interact with melanocortin receptors (MC4R/MC5R) and influence dopaminergic and serotonergic signaling pathways, though the precise mechanisms remain an area of ongoing investigation.
Semax Research Literature
Semax has a more developed research background compared to most synthetic peptides in this category. For example, one 2018 study examined BDNF levels in stroke patient rehabilitation contexts in relation to Semax administration. The majority of published studies originate from Russian research institutions, and methodological limitations — including small sample sizes and absence of placebo controls — are noted in the literature. Independent replication in Western research settings remains limited.
Semax holds approved pharmaceutical status in Russia, where it has been studied in neurological rehabilitation contexts.
What Is Adamax?
Adamax (also referred to as Acetyl-Semax, N-Acetyl Semax, or NA Semax) is a structural derivative of Semax. Its reported peptide sequence is Ac-Met–Glu–His–Phe–Pro–Gly–Pro–Ala–Gly (Ac-MEHFPGPAG).
Adamax differs from Semax in two structural respects: N-terminal acetylation and the addition of two amino acids at the C-terminus. Acetylation is a recognized modification technique used in peptide chemistry to reduce susceptibility to exopeptidase cleavage, which may theoretically affect stability and half-life in biological systems.
Adamax and Semax Compared
| Property | Semax | Adamax |
|---|---|---|
| Structure | ACTH(4–10) + Pro-Gly-Pro | Semax + N-terminal acetylation + C-terminal amidation |
| Stability | Shorter — susceptible to peptidase cleavage | Longer theoretical half-life due to terminus modifications |
| Receptor targets (proposed) | MC4R/MC5R; BDNF/NGF pathways | Same pharmacophore; modifications affect termini only |
| Research literature | Russian preclinical and clinical studies | No independent studies; mechanistic extrapolation from Semax only |
Research Context Summary
Semax has a documented research history and serves as a reference compound in neuropeptide studies. Adamax is a chemically modified derivative with a plausible structural rationale for altered stability, but currently lacks independent research validation.
Researchers working with either compound should consult the primary literature and treat Adamax findings as extrapolated from Semax data until dedicated studies are published.